Search for Companies, Tipsters or Sources…
Companies
Tipsters
Brokers
Sources
Or view the latest share tips
Company Results
Tipster results
Broker results
Sources results
Fund Manager results
Tips from these results
Recent Share tips:
- Buy Unilever (ULVR) by Harvey Jones in The Motley Fool
- Buy Legal & General Group (LGEN) by Christopher Ruane in The Motley Fool
- Buy Domino's Pizza Group (DOM) by Lucy Tobin in The Times - Tempus
- Buy Unilever (ULVR) by Charlie Keough in The Motley Fool
- Hold Elementis (ELM) by Tom Winnifrith in ShareProphets
- Sell Lifesafe Holdings (LIFS) by Steve Moore in ShareProphets
- Overweight Spectris (SXS) by Barclays
- Overweight Workspace Group (WKP) by Barclays
- Buy InterContinental Hotels Group (IHG) by Ben McPoland in The Motley Fool
- Avoid Kitwave Group (KITW) by Steve Moore in ShareProphets
- Buy Hiscox Limited (DI) (HSX) by Goldman Sachs
- Buy Rotork (ROR) by Jefferies
- Hold Telecom Plus (TEP) by Tom Winnifrith in ShareProphets
- Strong Buy OptiBiotix Health (OPTI) by Hot Stock Rockets in ShareProphets
- Avoid Surface Transforms (SCE) by Steve Moore in ShareProphets
- Buy InterContinental Hotels Group (IHG) by Bank of America
- Hold GSK (GSK) by DZ Bank
- Neutral Intertek Group (ITRK) by Goldman Sachs
- Neutral InterContinental Hotels Group (IHG) by Goldman Sachs
- Overweight Tesco (TSCO) by Barclays
Belluscura (BELL) Share Price
Health Care Sector
NOTE: This is based on 3 open tips for Belluscura (BELL)
| Latest Bid : 7.50p | Latest Ask : 8.00p |
| High Today : 8.00p | Low Today : 7.50p |
| This Years High : 50.00p | This Years Low : 7.25p |
| Volume : 31,596 | MKT Cap : £13.2M |
| Trading Velocity : Premium Only | Activity Score : Premium Only |
| Consensus Score : Premium Only | Momentum Score : Premium Only |
Belluscura (BELL) Overview
Belluscura focuses on novel oxygen-based treatment platforms that can be adapted and applied in a wide range of markets beyond those traditionally applicable to a single product or product line. Its range of portable products will be lighter / more adaptable / have higher O₂ capacity than existing oxygen enrichment products. Whilst potentially useful for recovering COVID patients, it has a wide range of use for sufferers of pneumonia / COPD (i.e. asthma/ emphysema /chronic bronchitis) and other respiratory illnesses.Belluscura (BELL) Latest Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Sell | Tom Winnifrith | Premium Only | 2024-01-02 08:10:00 02/01/2024 | 63.64% |
| Buy | Joanne Hart | Premium Only | 2022-11-12 21:50:00 12/11/2022 | -87.50% |
| Buy | Stuart Blair | Premium Only | 2021-08-02 08:55:00 02/08/2021 | -89.58% |
Belluscura (BELL) Active Short Positions
| Fund Manager | Position | Date | ||
|---|---|---|---|---|
| No active short positions | ||||
| Latest Bid : 7.50p | Latest Ask : 8.00p |
| High Today : 8.00p | Low Today : 7.50p |
| This Years High : 50.00p | This Years Low : 7.25p |
| Volume : 31,596 | MKT Cap : £13.2M |
Belluscura Overview
Belluscura focuses on novel oxygen-based treatment platforms that can be adapted and applied in a wide range of markets beyond those traditionally applicable to a single product or product line. Its range of portable products will be lighter / more adaptable / have higher O₂ capacity than existing oxygen enrichment products. Whilst potentially useful for recovering COVID patients, it has a wide range of use for sufferers of pneumonia / COPD (i.e. asthma/ emphysema /chronic bronchitis) and other respiratory illnesses.NOTE: This description is in part generated by ChatGPT and not an endorsement by or the opinion of Stockomendation Ltd.
Latest Belluscura Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Sell | Tom Winnifrith | Premium Only | 2024-01-02 08:10:00 02/01/2024 | 63.64% |
| Buy | Joanne Hart | Premium Only | 2022-11-12 21:50:00 12/11/2022 | -87.50% |
| Buy | Stuart Blair | Premium Only | 2021-08-02 08:55:00 02/08/2021 | -89.58% |